September 2, 2010 -- David Margolis, MD, professor of medicine, was interviewed by Simeon Bennett of Bloomberg Buisnessweek for his rearch using a cancer drug to kill HIV virus that lurks in patients receiving antiretroviral therapy. The story appears on the Bloomberg News website. A slightly different version appears in the print edition of Businessweek.
AIDS Quest to Kill 'SleepingVirus' Enlists Merck Cancer Drug
The 30-year-long search for a cure for AIDS, the world’s deadliest viral infection, may get a renewed boost from an unlikely source: a little-used Merck & Co. cancer drug.
Researchers at the University of North Carolina in Chapel Hill plan to test Merck’s drug, Zolinza, next year in about 20 people infected with HIV, the AIDS virus. The goal is to determine if Zolinza, or a medicine like it, can force HIV out of cells where it can reside, concealed from attack by potent antiviral treatments, said David Margolis, a professor of medicine who’s leading the research.